PinnyPeptide

FOX04-DRI vs MOTS-c

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

FOX04-DRI

Longevity

D-retro-inverso senolytic peptide — selectively kills senescent cells via FOXO4-p53 disruption.

Peptide B

MOTS-c

Longevity

Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis.

Typical vial

10 mg

Typical dose

Per kg dosing (research) mcg

Half-life

Extended via DRI backbone (~hours-days)

FDA status

Not FDA approved. In preclinical / early clinical developmen…

Typical vial

5 mg

Typical dose

5000-10000 mcg

Half-life

Not well characterized in humans (estimated hours based on peptide size)

FDA status

Not FDA approved. Investigational compound with no clinical …

FOX04-DRI effects

  • Selective induction of apoptosis in senescent cells
  • Reduction of senescence-associated secretory phenotype (SASP)
  • Rejuvenation effects in aged mouse models (single study)
  • Mechanistically based on FOXO4-p53 binding disruption
  • D-retro-inverso backbone provides enzymatic stability

MOTS-c effects

  • Activates AMPK pathway to enhance metabolic homeostasis
  • Improves insulin sensitivity and glucose uptake
  • Promotes fatty acid oxidation and reduces fat accumulation
  • Mimics exercise-induced metabolic adaptations
  • Preserves skeletal muscle function during aging
  • Enhances mitochondrial biogenesis and function

FOX04-DRI side effects

  • Largely uncharacterized in humans
  • Theoretical: off-target apoptosis in non-senescent cells under p53 stress
  • Injection-site reactions
  • Possible effects on stem/progenitor cell populations
  • Acute inflammatory response from senescent-cell debris

MOTS-c side effects

  • Injection site reactions (redness, mild pain)
  • Transient changes in blood glucose levels
  • Mild fatigue during initial dosing
  • Limited human safety data available

FOX04-DRI dosing ranges

Senolytic research (research-only)

0.4-5 mg/kg · Every other day for 1-2 weeks per cycle · Cycle-based per protocol

MOTS-c dosing ranges

Metabolic optimization and longevity

5-10 mg · Three to five times weekly (SubQ) · 4-8 weeks

Full FOX04-DRI guide → Full MOTS-c guide →

FOX04-DRI vs MOTS-c — common questions

What is the difference between FOX04-DRI and MOTS-c?

FOX04-DRI: D-retro-inverso senolytic peptide — selectively kills senescent cells via FOXO4-p53 disruption. Typical dose Per kg dosing (research) mcg. MOTS-c: Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis. Typical dose 5000-10000 mcg. Both fall under the Longevity category.

Can you stack FOX04-DRI and MOTS-c?

Stacking FOX04-DRI with MOTS-c is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, FOX04-DRI or MOTS-c?

FOX04-DRI is typically dosed: Every other day for 1-2 weeks per cycle for Senolytic research (research-only). MOTS-c is typically dosed: Three to five times weekly (SubQ) for Metabolic optimization and longevity.

Are FOX04-DRI and MOTS-c FDA approved?

FOX04-DRI: Not FDA approved. In preclinical / early clinical development as Proxofim (Cleara Biotech). MOTS-c: Not FDA approved. Investigational compound with no clinical trials completed for regulatory submission.

Related peptide comparisons

epithalon vs fox04-drifox04-dri vs n-acetyl-epitalonfox04-dri vs nad-plusfox04-dri vs ss-31epithalon vs mots-cmots-c vs n-acetyl-epitalon

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free